capmatinib (Tabrecta)

Indications

• adults with metastatic non-small cell lung cancer (NSCLC) with c-MET gene exon 14 skipping

Dosage

• 400mg PO BID ith or without food

Tabs: 150 & 200 mg

Adverse effects

• most common (> 20%)
  • peripheral edema, nausea/vomiting, fatigue, dyspnea, decreased appetite
• photosensitivity
• serious: interstitial lung disease/pneumonitis, hepatotoxicity

• drug adverse effects of tyrosine kinase inhibitor(s)

Drug interactions

• avoid strong & moderate CYP3A inducers

Mechanism of action

• tyrosine kinase inhibitor targeting c-met protein

More general terms

• small inhibitory antineoplastic agent (ib drug)
• tyrosine kinase inhibitor

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25145656
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=44513225
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=122201352
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=137347172